Green Alpha Advisors LLC Raises Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Green Alpha Advisors LLC grew its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 28.6% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 24,629 shares of the company’s stock after acquiring an additional 5,471 shares during the quarter. Green Alpha Advisors LLC’s holdings in CRISPR Therapeutics were worth $969,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of CRSP. Northwestern Mutual Wealth Management Co. lifted its holdings in CRISPR Therapeutics by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock valued at $249,000 after acquiring an additional 211 shares during the period. Boston Family Office LLC increased its position in shares of CRISPR Therapeutics by 2.2% during the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares during the last quarter. Bedell Frazier Investment Counselling LLC lifted its stake in shares of CRISPR Therapeutics by 0.8% in the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock worth $1,238,000 after purchasing an additional 218 shares during the period. National Bank of Canada FI boosted its holdings in shares of CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock worth $46,000 after buying an additional 220 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in CRISPR Therapeutics by 1.9% during the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after buying an additional 231 shares during the period. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on CRSP shares. Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Chardan Capital restated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Bank of America lowered their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $78.38.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 30,000 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the transaction, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. This trade represents a 13.24 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Stock Down 3.9 %

Shares of CRISPR Therapeutics stock opened at $39.69 on Monday. CRISPR Therapeutics AG has a twelve month low of $38.20 and a twelve month high of $91.10. The business has a 50-day moving average price of $46.17 and a 200-day moving average price of $48.60. The firm has a market cap of $3.39 billion, a price-to-earnings ratio of -14.02 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same quarter last year, the business posted ($1.41) EPS. On average, equities analysts expect that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.